Skip to content
Search AI Powered

Latest Stories

New CPCF arrangements: Community pharmacy secures largest funding boost in NHS

The baseline annual CPCF funding for 2025/26 will rise to £3.073 billion, with £900 million allocated to the margin.

 New CPCF arrangements: Community pharmacy secures record £617m funding boost

This record investment is a vital first step to getting community pharmacies back on their feet and fit for the future, says health minister Stephen Kinnock.

Photo credit: gettyimages

Following a six-week consultation with Community Pharmacy England (CPE), the government has committed an additional £617 million over two years to support the sector- the largest uplift in funding across the whole of the NHS.

The Department of Health & Social Care (DHSC) today (31) announced the funding arrangements for the Community Pharmacy Contractual Framework (CPCF) for 2024/25 and 2025/26.


The deal includes a final funding settlement for this year (2024/25), providing an extra £106m compared to the previous year, and a further £375m for 2025/26.

It takes the baseline annual CPCF funding for 2025/26 to £3.073 billion, representing a 15% increase in government spending on the previous year, surpassing the record 5.8% growth in the total NHS budget.

From April 2025, the margin allowance for community pharmacy will rise to £900 million per year.

The sector has also secured a further £215 million for Pharmacy First and other Primary Care Recovery Plan services.

In a major relief to pharmacy owners, the government has agreed to write off £193 million of historic medicines margin over delivery, primarily accrued during the COVID-19 pandemic.

Health minister Stephen Kinnock described this record investment and reform as “a vital first step to getting community pharmacies back on their feet and fit for the future.”

“Community pharmacists are at the heart of local healthcare, and we want them to play a bigger role as we shift care out of hospitals and into the community through our Plan for Change,” he said.

“We’re working to turn around a decade of underfunding and neglect that has left the sector on the brink of collapse.”

“The agreement shows how this government is working in partnership with community pharmacy to deliver more care for patients closer to their home, freeing up GP appointments, and catching ill-health earlier and preventing it in the first place,” he added.

CPE chief executive Janet Morrison pointed out that a decade of real-terms funding cuts has left pharmacy businesses fighting to survive, with closures continuing at an alarming rate.

She said: “We are pleased that this settlement takes a positive first step in the right direction for pharmacies, towards stabilisation and a better future.

“A sustainable community pharmacy sector can and must play a huge part in the future of the NHS.”

Fee Adjustments

As part of the new agreement, the following fee changes will take effect from April 2025:

Single Activity Fee (SAF): Increasing from £1.27 to £1.46 per item.

Pharmacy Contraception Service (PCS): Fees for both initiation and continuation consultations will rise from £18 to £25.

Pharmacy First Service: Consultation fees for Minor Illness and Clinical Pathways will increase from £15 to £17.

New Medicine Service (NMS): The payment structure will be simplified, introducing a split fee—£14 for the initial intervention consultation and an additional £14 for the follow-up consultation.

Hypertension Case Finding Service:

Clinic Check Consultation fee will be reduced from £15 to £10.

Ambulatory Blood Pressure Monitoring (ABPM) fee will increase from £45 to £50.85.

Expansion of two existing services

The government has also confirmed the expansion of the New Medicine Service (NMS) and Pharmacy Contraception Service (PCS).

From October 2025, antidepressants will be added to the NMS, and Emergency Hormonal Contraception (EHC) will be added to the PCS, with a consultation fee of £20.

Additionally, the government has agreed to enhance the use of skill mix within the Smoking Cessation Service and Pharmacy Contraception Service, allowing pharmacy technicians to deliver Patient Group Directions (PGDs).

From 2025/26, PGDs will be introduced for the Smoking Cessation Service to allow the supply of varenicline and cytisinicline (cytisine), while drospirenone will be added under PGD for the Pharmacy Contraception Service.

A smaller than usual Pharmacy Quality Scheme (PQS) will include training to support the expansion of these services, with a 75% aspiration payment available to claim in May.

"This positive investment underscores the importance of community pharmacy as an integral part of the NHS team, providing clinical care, optimising the use of medicines, and supporting people in their neighbourhoods to prevent ill-health, said David Webb, chief pharmaceutical officer for England.

Amanda Doyle, national director for primary care and community services, welcomed the funding deal, emphasising that it will empower community pharmacists to build on their success and further expand their roles in patient care.

“This funding secures their good work for patients for the future,” she stated.

The announcement comes after the release of an independent economic analysis of England’s community pharmacy sector on Friday, which revealed that 78% of pharmacies are "unsustainable in the short run" and face a significant risk of disrupting NHS pharmaceutical services.

More For You

The Complete Anti-Inflammatory Guide - a useful resource for pharmacists to support patient health and wellbeing

Chronic inflammation is linked to more than 50 per cent of all deaths worldwide and one in five cancers.

The Complete Anti-Inflammatory Guide - a useful resource for pharmacists to support patient health and wellbeing

When Hemant Patel was struck down by Covid, he was determined to discover what was it that led to the disease having a devastating impact on the lives of people who seemed be healthy – the culmination of his journey is the book, The Complete Anti-Inflammatory Guide.

“I was gasping for breath and counting the number of days I might be alive when I was infected with Covid,” reveals Patel.

Keep ReadingShow less
Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less